Geron Corp. (NASDAQ:GERN) on March 03, reported a loss of $8.9 million in its fourth quarter. The Menlo Park, California-based company said it had a loss of 6 cents per share. On Friday shares of Geron Corporation (NASDAQ:GERN) closed at $3.50. Company’s sales growth for last 5 years was -14.20% and EPS growth for next 5 years is recorded as 5.00%.
Centrus Energy Corp. (NYSE:LEU) announced that Daniel B. Poneman has been selected by its Board of Directors as president and chief executive officer of the Company. The former deputy secretary of energy will join Centrus immediately and will become the chief executive later this month. Poneman will also be a member of the board. Centrus Energy Corp. (NYSE:LEU) in last trading activity moved up 2.34% to close at $4.37. Company weekly performance is 4.80% while its quarterly performance stands at -18.47%. Centrus Energy Corp. (NYSE:LEU) is -96.78% away from its 52 week high.
On last trading day TransDigm Group Incorporated (NYSE:TDG) moved down -1.03% to close at $213.12. Its volatility for the week is 1.43% while volatility for the month is 1.56%. TDG’s sales growth for past 5 years was 25.50% and its EPS growth for past 5 years was -0.40%. TransDigm Group Incorporated (NYSE:TDG) monthly performance is 1.64%.
On March 5, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced that it has acquired the approved abbreviated new drug application (“ANDA”) for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. According to IMS Health, the overall market for this product was approximately $39 million in 2014. Guggenheim set a $79.00 price objective on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Friday morning. The firm currently has a a buy rating on the stock. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has 1.90% insider ownership while its institutional ownership stands at 83.60%. In last trading activity company’s stock closed at $66.72.
Hospira Inc. (NYSE:HSP), applauds Sandoz and the U.S. Food and Drug Administration (FDA) on FDA approval of the first biosimilar in the United States. This is a watershed moment for improving patient access to safe, effective and more affordable biologic medicines. As a leading global provider of biosimilars, Hospira has seen first-hand the positive impact of biosimilars in other countries, and we are a proud participant in these early stages of the development of a pathway for these medicines in the United States. On last trading day Hospira Inc. (NYSE:HSP) moved up 0.06% to close at $87.90. Its volatility for the week is 0.25% while volatility for the month is 0.19%. HSP’s sales growth for past 5 years was 2.80% and its EPS growth for past 5 years was -4.60%. Hospira Inc. (NYSE:HSP) monthly performance is 35.65%.